Treatment for patients with metastatic melanoma is inadequate. A subset of metastatic melanomapatients can undergo meaningful tumor regression in response to agents that modify lymphocyte activationand/or expansion, for example, IL-2, anti-CTLA4, or IL-2 in combination with transfer of ex vivo expandedtumor-infiltrating lymphocytes (TIL). However, most patients receiving these therapies fail to respond or toachieve lasting benefit. Preclinical studies conducted in our laboratories and confirmed by other investigatorsprovide strong evidence that inhibition of TGF-beta signaling can markedly enhance the anti-tumor activity ofCD8+ cytotoxic T-lymphocytes (CTL) in animal models. We propose to extend these studies to determineoptimal approaches for clinical development of agents that inhibit TGF-beta signaling in combination with IL-2,IL-2 + TIL, anti-CTLA4, or other related immunotherapeutic manipulations. The goal of the clinical trialsproposed in this application is to improve the rate and quality of tumor responses in patients with metastaticmelanoma and to reduce the morbidity and mortality from this disease.
In Aim 1 we propose to confirm the improved anti-tumor effects of CD8+ TGFRII-DNR cells (CD8+lymphocytes with the transgene for the dominant negative transforming growth factor beta receptor II) in mousemodels and to determine if the anti-tumor activity of CD8+ TGFRII-DNR cells can be improved by addition ofIL-2, addition of anti-CTLA4, and/or addition of anti-CD137. Furthermore, we propose to further characterizethe mechanisms by which TGF-betaattenuates anti-tumor lymphocyte responses, in particular, to determine ifthe effects of TGF-beta are directly on CD8+ CTL or indirectly through induction of Treg (T regulatory cellswhich inhibit CD8+ and CD4+ anti-tumor lymphocyte responses), to determine the role of tumor driven TGF-beta in induction of Treg, and to determine whether and how Treg attenuate CD8+ CTL mediated tumorrejection.
In Aim 2, we propose to create a retroviral vector carrying the TGFRII-DNR gene suitable for usein human clinical trials, to develop methods for transduction and expansion of human melanoma-derived TIL,and to characterize the cell product. We will also use mouse melanoma models to determine the optimalconditions necessary to maximize the anti-tumor effects of TGFRII-DNR CTL, and will use the results of theexperiments to guide the design of a clinical trial.
In Aim 3, we propose to evaluate non-genetic(pharmacologic) approaches to inhibit TGF-beta combined with an immunotherapy. Finally, in Aim 4, wepropose to conduct proof of concept clinical trials in which TGF-beta inhibition is combined with an immunetherapy. We propose that one of the clinical trials will involve adoptive transfer of melanoma TIL carrying thegene for TGFRII-DNR.
Showing the most recent 10 out of 172 publications
